|1.||Ma, Tina: 1 article (06/2005)|
|2.||Lee, David: 1 article (06/2005)|
|3.||Nagle, Barbara: 1 article (06/2005)|
|4.||Schlagheck, Thomas G: 1 article (06/2005)|
|5.||Galer, Bradley S: 1 article (06/2005)|
|6.||Monck, Nat: 1 article (03/2002)|
|7.||Katz, N P: 1 article (01/2000)|
|8.||Chevlen, E: 1 article (01/2000)|
|9.||Caruso, F S: 1 article (01/2000)|
01/01/2000 - "MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients."
01/01/2000 - "To determine the appropriate conversion regimens from other oral or transdermal opioid analgesics to MorphiDex (MS:DM), 592 patients with moderate to severe chronic pain requiring daily use of opioid analgesics were enrolled in this multicenter, open-label study. "
03/01/2002 - "Endo (which acquired Algos in July 2000) has developed EN-3231, a combination of morphine and dextromethorphan, for the treatment of moderate-to-severe chronic pain. "
01/01/2000 - "MorphiDex, a 1:1 combination of dextromethorphan and morphine, provides satisfactory pain control at a significantly lower morphine daily dose. "
01/01/2000 - "MorphiDex (MS:DM), a 1:1 (weight:weight) ratio of morphine sulfate (MS) to dextromethorphan hydrobromide (DM), is under clinical development for the treatment of moderate to severe pain. "
|1.||Morphine (MS Contin)
|3.||Opioid Analgesics (Opioids)